These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 29338466

  • 1. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H, Henchcliffe C.
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [Abstract] [Full Text] [Related]

  • 2. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N.
    Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
    [Abstract] [Full Text] [Related]

  • 3. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC, Hauser RA.
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [Abstract] [Full Text] [Related]

  • 4. Valbenazine: First Global Approval.
    Kim ES.
    Drugs; 2017 Jul; 77(10):1123-1129. PubMed ID: 28578484
    [Abstract] [Full Text] [Related]

  • 5. Valbenazine in the treatment of tardive dyskinesia.
    Witek N, Comella C.
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [Abstract] [Full Text] [Related]

  • 6. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N, Jankovic J.
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [Abstract] [Full Text] [Related]

  • 7. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L.
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [Abstract] [Full Text] [Related]

  • 8. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
    Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV.
    N Engl J Med; 2017 Jun 29; 376(26):2503-2506. PubMed ID: 28489481
    [No Abstract] [Full Text] [Related]

  • 9. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.
    Am J Psychiatry; 2017 May 01; 174(5):476-484. PubMed ID: 28320223
    [Abstract] [Full Text] [Related]

  • 10. Valbenazine for Tardive Dyskinesia.
    Freudenreich O, Remington G.
    Clin Schizophr Relat Psychoses; 2017 May 01; 11(2):113-119. PubMed ID: 28742396
    [Abstract] [Full Text] [Related]

  • 11. Valbenazine (Ingrezza) for tardive dyskinesia.
    Med Lett Drugs Ther; 2017 May 22; 59(1521):83-84. PubMed ID: 28520698
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN, Aggarwal S, Yonan C.
    J Comp Eff Res; 2018 Feb 22; 7(2):135-148. PubMed ID: 28965423
    [Abstract] [Full Text] [Related]

  • 13. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
    Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang GS, O'Brien CF.
    J Clin Psychiatry; 2017 Feb 22; 78(9):1344-1350. PubMed ID: 29141124
    [Abstract] [Full Text] [Related]

  • 14. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M, Pigato G, Kane JM, Correll CU.
    Drug Des Devel Ther; 2018 Feb 22; 12():1215-1238. PubMed ID: 29795977
    [Abstract] [Full Text] [Related]

  • 15. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS, Calabrese JR, Nierenberg AA, Farahmand K, Yonan C, Siegert S, Burke J.
    J Affect Disord; 2019 Mar 01; 246():217-223. PubMed ID: 30583148
    [Abstract] [Full Text] [Related]

  • 16. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
    Kim AP, Baker DE, Levien TL.
    Consult Pharm; 2018 Apr 01; 33(4):201-209. PubMed ID: 29609698
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU, Josiassen RC, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):53-60. PubMed ID: 28839340
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM, Correll CU, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):69-76. PubMed ID: 28839342
    [Abstract] [Full Text] [Related]

  • 19. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM.
    CNS Spectr; 2018 Aug 01; 23(4):239-247. PubMed ID: 30160230
    [Abstract] [Full Text] [Related]

  • 20. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):61-68. PubMed ID: 28839341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.